All In Biotech

NDA 214070 · Astrazeneca

Airsupra

Albuterol Sulfate, Budesonide · Inhalation · Corticosteroid

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jan 10, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

793

238 Phase 3, 24 recruiting

FAERS reports

1,599

319 serious, 18 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2025.

AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. AIRSUPRA is a combination of albuterol, a beta 2 -adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. ( 1 )

Mechanism: AIRSUPRA contains both albuterol and budesonide; therefore, the mechanisms of action described below for the individual components apply to AIRSUPRA. These drugs represent two classes of medications (a short-acting selective beta 2 -adrenergic agonist and a synthetic corticosteroid) that have different effects on clinical, physiological, and inflammatory indices of asthma. Albuterol In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. Although beta 2 -adrenoceptors are the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AIRSUPRA · ALBUTEROL SULFATE EQ 0.09MG BASE/INH; BUDESONIDE 0.08MG/INH · AEROSOL, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Albuterol" as an intervention, any sponsor and status, largest first.

All 793 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • device delivery system issue422
  • product dose omission issue261
  • asthma197
  • dyspnoea183
  • device malfunction179
  • wrong technique in device usage process168
  • drug ineffective137
  • wrong technique in product usage process134
  • incorrect dose administered by device130
  • device use issue128
  • cough110
  • incorrect dose administered95

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20204
20211
20227
202314
2024208
2025784
2026581

Recalls

1 FDA enforcement reports for this application.

  • May 14, 2025 · Class II · Ongoing

    Defective delivery system

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Airsupra (Albuterol Sulfate/Budesonide)

2024 spending

$24.8M

Beneficiaries

25,835

46,082 claims

Per beneficiary

$961

$43.56 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$925,019
2024$24,827,278

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 985 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.